- NKTR has an average dollar-volume (as measured by average daily share volume multiplied by share price) of $45 million
- NKTR has traded 331,158 shares today
- NKTR is trading at 4.06 times the normal volume for the stock at this time of day
- NKTR is trading at a new low 3.03468259872389989340035754139535129070281982421875 below yesterday's close
'Weak on High Relative Volume' stocks are worth watching because major volume moves tend to indicate underlying activity such as material stock news, analyst downgrades, insider selling, selling from 'superinvestors,' or that hedge funds and traders are piling out of a stock ahead of a catalyst. Regardless of the impetus behind the price and volume action, when a stock moves with strength and volume it can indicate the start of a new trend on which early investors can capitalize (or avoid losses by trimming weak positions). In the event of a well-timed trading opportunity, combining technical indicators with fundamental trends and a disciplined trading methodology should help you take the first steps towards investment success. EXCLUSIVE OFFER: Get the inside scoop on opportunities in NKTR with the Ticky from Trade-Ideas. See the FREE profile for NKTR NOW at Trade-Ideas More details on NKTR: Nektar Therapeutics, a biopharmaceutical company, develops drug candidates that utilize its PEGylation and polymer conjugate technology platforms in the United States. Its product pipeline includes drug candidates in therapeutic areas comprising oncology, pain, anti-infectives, and immunology. NKTR has a PE ratio of 67. Currently there are seven analysts that rate Nektar Therapeutics a buy, one analyst rates it a sell, and none rate it a hold. The average volume for Nektar Therapeutics has been 1.7 million shares per day over the past 30 days. Nektar has a market cap of $1.77 billion and is part of the health care sector and drugs industry. The stock has a beta of 1.31 and a short float of 17.1% with 5.41 days to cover. Shares are down 10.7% year-to-date as of the close of trading on Thursday. EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE. TheStreetRatings.com Analysis: TheStreet Quant Ratings rates Nektar Therapeutics as a hold. The company's strengths can be seen in multiple areas, such as its notable return on equity, robust revenue growth and good cash flow from operations. However, as a counter to these strengths, we also find weaknesses including a generally disappointing performance in the stock itself and generally higher debt management risk. Highlights from the ratings report include:
- When compared to other companies in the Pharmaceuticals industry and the overall market, NEKTAR THERAPEUTICS's return on equity exceeds that of the industry average and significantly exceeds that of the S&P 500.
- NKTR's very impressive revenue growth greatly exceeded the industry average of 2.1%. Since the same quarter one year prior, revenues leaped by 450.3%. Growth in the company's revenue appears to have helped boost the earnings per share.
- 42.29% is the gross profit margin for NEKTAR THERAPEUTICS which we consider to be strong. It has increased significantly from the same period last year. Regardless of the strong results of the gross profit margin, the net profit margin of 31.08% trails the industry average.
- The debt-to-equity ratio is very high at 3.32 and currently higher than the industry average, implying increased risk associated with the management of debt levels within the company. Despite the company's weak debt-to-equity ratio, the company has managed to keep a very strong quick ratio of 4.36, which shows the ability to cover short-term cash needs.
- NKTR has underperformed the S&P 500 Index, declining 15.05% from its price level of one year ago. Looking ahead, other than the push or pull of the broad market, we do not see anything in the company's numbers that may help reverse the decline experienced over the past 12 months. Despite the past decline, the stock is still selling for more than most others in its industry.
- You can view the full Nektar Therapeutics Ratings Report
EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.